

Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

CVS Health, Inc. Director Jean-Pierre Millon will serve as Chairman of the BAB, Roger Formisano and Robert Hopkins to serve as BAB board members for Regen BioPharma Inc.

SAN DIEGO, October 30, 2017 /PRNewswire/ --

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB). The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB. The advisory board will assist Regen's management team in evaluating partnership and licensing opportunities related to the company's intellectual property including its NR2F6 program.

"We are pleased to have such a highly accomplished and respected group of individuals join our advisory board," said Todd Caven, CFO at Regen BioPharma. "Their collective insight and expertise will be extremely helpful to the executive team as we evaluate various opportunities with respect to our intellectual property portfolio in 2018 and beyond."

The initial members of the board are as follows:

Jean-Pierre Millon (Chairman) is a director at CVS Health, Inc. [NYSE: CVS]. His board position evolved after a CVS merger with Caremark in April 2007 and Caremark's purchase of AdvancePCS, a pharmacy benefit management company, in 2004. Before his post with Caremark, Mr. Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. He was president and chief executive officer of PCS from 1996 to 2000. Prior to joining PCS, Mr. Millon was an executive with Eli Lilly and Company. His career with Lilly and its subsidiaries spanned two decades and was highlighted by leadership positions in the United States and executive posts in Asia, Europe and the Caribbean Basin. A native of Paris, Mr. Millon is fluent in French, English, German and Spanish.

Roger Formisano, PhD (board member) is Vice-President for Leadership and Strategic Development at UW Health in Madison, Wisconsin, where he designed, developed and delivered a Physician Leadership Development Program, grooming mid-career physicians for leadership roles in the \$3.5 billion UW Health organization. He is a recognized thought leader on strategy, entrepreneurship and organizational effectiveness and has distinguished himself as a professor, an author, and a senior executive. He has served as a professor of entrepreneurship and business at UW-Madison School of Business, ISTCE-INDEG in Lisbon, Portugal and HEC Paris.

Robert Hopkins (board member) spent his career in hospital systems management, including C-level positions in marketing, operations, physician practice management, business development and as a chief executive. He earned his B.A. in Journalism and MBA from the Smeal College of Business at Pennsylvania State University. Additionally, he completed the Graduate Certificate Program in Medical Ethics at Albany Medical College. He retired in 2015 and is a private investor, including investment in Regen BioPharma.

"The marketplace for small molecule drug platforms in the immune oncology and autoimmunity sectors of pharmacology continues to attract great interest from pharmaceutical firms throughout the world," said David Koos, Chairman and CEO of Regen. "Within the small molecule universe, Regen possesses an extremely unique position as it pertains to NR2F6. We look forward with great anticipation to the insight that we will receive from our advisory board as to the optimal strategies to expand our NR2F6 program and increase shareholder value."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/ II clinical trials. Additional information on Regen BioPharma is available at <http://www.regenbiopharmainc.com>.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.

David R. Koos, Ph.D.

Chairman & Chief Executive Officer

+1-619-702-1404 Phone

+1-619-330-2328 Fax

<http://www.regenbiopharma.com>

david.koos@regenbiopharma.com

SOURCE Regen BioPharma, Inc.